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CASE REPORT
CARRION´S DISEASE (BARTONELLOSIS BACILLIFORMIS) CONFIRMED BY HISTOPATHOLOGY IN
THE HIGH FOREST OF PERU
Vicente MACO(1,2), Ciro MAGUIÑA(1,3), Antonio TIRADO(2), Vicente MACO C.(4) & José E. VIDAL(5)
SUMMARY
Bartonellosis or Carrion´s disease is endemic in some regions of Peru, classically found in the inter-Andean valleys located
between 500 and 3200 meters above sea level. We report the case of a 43 year-old male patient, farmer, who was born in the Pichanaki
district (Chanchamayo, Junin), located in the High Forest of Peru. He presented with disseminated, raised, erythematous cutaneous
lesions, some of which bled. The distribution of these lesions included the nasal mucosa and penile region. Additionally subcutaneous
nodules were distributed over the trunk and extremities. Hematologic exams showed a moderate anemia. Serologic studies for HIV
and Treponema pallidum were negative. The histopathologic results of two biopsies were compatible with Peruvian wart. Oral
treatment with ciprofloxacin (500 mg BID) was begun. Over 10 days, the patient showed clinical improvement. This is the first report
of a confirmed case of bartonellosis in the eruptive phase originating from the Peruvian High Forest, showing the geographical
expansion of the Carrion´s disease.
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INTRODUCTION
The infections caused by the pathogens of the genus Bartonella
comprise a heterogeneous group of emerging and reemerging
diseases2,12,13,20. At the present time, 20 species have been described, eight
of which affect humans, particularly Bartonella bacilliformis, described
in 1905 and responsible for Carrion´s disease. The Carrion´s disease is
an reemerging illness native to Peru, present since the pre-Columbian
period14,15, found in the inter-Andean valleys between 500 and 3,200
meters above sea level, between the 2º north latitude and 13º south
latitude, where ecological conditions for the development for Lutzomyia
verrucarum, the main vector involved in its transmission, are found6,16.
It has been estimated that the population at risk is 1,686,236 inhabitants16
distributed in a surface of 144,496 km². There have also been cases
described in rural areas of Ecuador and Colombia1,22. The illness develops
through two phases: the acute hematic phase, or Oroya fever, and the
eruptive phase or Peruvian wart, both separated by an asymptomatic
period. The acute phase is characterized by fever, moderate to severe
pallor, general discomfort and myalgias. Neurological complications (i.e.
altered mental status, ataxia, seizure, agitation, coma), heart complications
(i.e. congestive heart failure, pericardial effusions, myocarditis) and
respiratory complications (i.e. adult respiratory distress syndrome) there
has been related in severe cases. Approximately one third of patients
present with opportunistic infections due to non-typhoid Salmonellas
(i.e. S. dublin, S. typhymurium, S. anatum), sepsis by Shigella dysenteriae,
Enterobacter, Pseudomona aeruginosa, Staphylococcus aureus,
pneumonia by Pneumocystis jirovecii or reactivation of tuberculosis,
toxoplasmosis, and histoplasmosis. Fatality among untreated patients
varies generally among 40 to 88%10. With prompt treatment, fatality is
reduced to less than 9% of admitted patients13. A recent report after an
outbreak of bartonellosis in a non-endemic area suggested that the illness
seems to be significantly more benign than that frequently reported10.
After weeks or months of the acute phase, less than 10% of the patients
will progress to the eruptive phase13,22. This phase is characterized for
the presence of diverse cutaneous lesions, in which the patient develops
nodular dermal eruptions known as Peruvian wart, classified in three
types: miliary (erythematous papules, less than 3 mm, frequently
numerous and occasionally pruritic), mulaire (erythematous round lesion,
over 5 mm, frequently eroded and sessile), and nodular (subdermal
nodules)12. Characteristically, the lesions are painless and prone to bleed.
In this study we report the first confirmed case of Carrion´s disease
in the eruptive phase to originate in the High Forest of Peru, previously
considered a non-endemic area of bartonellosis.
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CASE REPORT
A 43 year-old male farmer was admitted to the Pichanaki Hospital
(Fig. 1) in June of the 2003, after 6 weeks of illness. The illness was first
characterized by reddish cutaneous lesions approximately 2 mm diameter
in the left forearm which were not painful. The lesions continuously
enlarged in size over the following three weeks. They were removed by
the patient and resulted in light bleeding. Four weeks before presentation,
the patient noticed similar lesions in the upper and lower extremities and
over the thorax, progressively increasing in number and size and spreading
to the face, hair and nose. One week before arriving into the hospital, the
patient went to another hospital, where he was prescribed oral dicloxacillin
(500 mg QID), without improvement. He denied having lived or traveled
to endemic areas of Carrion´s disease. Likewise, he denied previous
illnesses, hospitalizations and prior surgical interventions.
Physical exam showed moderate pallor of skin and mucosa. Multiple
cherry red papules and nodular lesions were seen, between 0.3 to 1 cm
of diameter, located in the scalp, neck, face (Fig. 2), thorax, abdomen,
upper and lower extremities, some of them eroded with signs of recent
bleeding. Likewise, a 2 mm papular reddish wound was found in the
penis and nodular subcutaneous wounds in the periumbilical and
epitrochlear region, thigh and in nasal alae. The remainder of the exam
was normal.
Hematologic studies showed moderate anemia with a hematocrit of
34% and RBCs count of 5,700 cells/mm3. Serologic studies for human
immunodeficiency virus and Treponema pallidum were negative. Biopsy
of two lesions was performed. Microscopy study showed marked vascular
proliferation with prominent endothelium and stromal angiosarcomal
cells, arranged in nodules. In the interstitium was visualized the presence
of mature lymphocytic inflammatory cells and evidence of ischemic
necrosis with hemorrhage and dense infiltration of mixed inflammatory
cells, lymphocytes and polymorphonuclear cells, without cellular typing
(Fig. 3). They were identified as the mulaire and the nodular or subdermal
types of the eruptive phase of the Carrion´s disease. Once the diagnosis
was determined, the lesions were quantified and classified, and a total of
191 were identified. The majority were warts of the miliary type (58.6%),
followed by the mulaire type (36.6%) and the nodular type (4.7%). The
treatment was initiated with oral ciprofloxacin (500 mg BID) for 10
days. On the fifth day of treatment there was a decrease in the size of the
miliary lesions. The patient was released and returned five days after
completing treatment. At the time, the miliary warts had disappeared,
including the penile lesion, and the size of the nodular lesions had
decreased by approximately 50%.
DISCUSSION
This is the first histopathologically confirmed case of Carrion’s disease
in the eruptive phase found in the Peruvian High Forest. Previous reports
have documented isolated cases as well as an epidemic cluster of the
hemolytic phase in this region. Nevertheless, no evidence of the presence
of the complete cycle of the illness existed previously. The first report of a
patient in the high forest was described by LOJA et al. in 1994. The case
described the acute phase, in Quillabamba (Cuzco), found in a patient
who lived at 1,047 meters above sea level11. Our patient was from the high
forest in the Pichanaki district (Chanchamayo, Junin), located at 525 meters
Fig. 1 - Geographical location of Pichanaki district (*), in Junin, new reported endemic area
of human bartonellosis in Peru.
Fig. 2 - Miliary (left arrow) and mulaire (right arrow) lesions.
Fig. 3 - Histopathology (H-E 400X). Biopsy of skin showing intense neovascularization and
diffuse infiltrate of lymphocytes, accompanied by some histiocytes and extravasated red blood
cells.
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above sea level. This area was previously known as a non-endemic area.
The first epidemic cluster that showed the presence of the Carrion’s disease
in the Peruvian forest occurred between October 1992 and April 1993 in
the Aguarunas communities in the province of San Ignacio (Cajamarca).
Seven patients were detected who had peripheral blood smears consistent
with infection by B. bacilliformis16. No patient presented in the eruptive
phase. Between 1996 and 1997 a bartonellosis cluster was found in the
department of Amazonas, where several cases of Peruvian wart were
confirmed with histopathology10. However, the cases originated more
commonly from mountainous districts rather than the forest of Peru.
Because of the lack of information about the exact origin of the wart cases,
our report constitutes the first case confirmed in the Peruvian Forest.
In recent years, Carrion’s disease clusters continued to be detected
in Peru. Between April and June of 1998 there were 26 reported cases
confirmed in the Sacred Valley of the Incas (Cuzco), the majority of
which were children. These cases had a fatality rate of 23%19. On the
other hand, between January and December of 1998 there were 71
reported cases of the acute phase and 121 in the eruptive phase in the
province of Antonio Raymondi (Ancash)7.
The recognition of a new endemic area of Carrion’s disease has an
enormous epidemiological significance. In the district where our patient
lives, there are approximately 3,700 families: 3,000 in urban zones
(16,000 inhabitants), and 700 in rural areas (24,000 inhabitants). All
this population is therefore at risk to acquire the illness.
At the present time, there have been reported cases of Carrion’s
disease clusters in 12 of the 24 departments of Peru. Ancash is the area
with the highest number of cases in both acute hemolytic phase and the
eruptive one, as well as the highest rates of incidence12,14,16,17. Five of
these departments (Cajamarca, Junín, Huánuco, Amazonas, and Cuzco)
have some districts located in the Peruvian Forest.
The acute phase of Carrion’s disease has also been described in other
non-endemic areas. Among them, the most severely affected districts
are Chincha (Ica) and Pasamayo-Boza (Huaral, Lima)18. Both are coastal
cities, out of the traditional ecological niches for bartonellosis. These
findings present the possibility of the extension of Carrion’s disease not
only to the forest of Peru, as it establishes of final form our report, but
also to the Peruvian coast, in areas situated at less than 500 m above sea
level, suggesting important epidemiological changes.
Carrion’s disease evolves through several phases. Some studies show
that to 60% of the population in endemic areas are asymptomatic and
have no known history of bartonellosis, but have positive serology for
B. bacilliformis8. On the other hand, the acute hemolytic phase does not
represent a sine qua non condition for the presence of the eruptive phase.
This partially explains why the complete cycle of the illness had not
been described in the Peruvian forest. Finally, as confirmed in our report,
the inhabitants of endemic areas can develop the eruptive phase as the
only manifestation of the illness10,13.
The clinical manifestations of Carrion’s disease have been well-
studied2,12,13,20,22. Characteristically, the lesions of the eruptive phase are
found predominantly on the upper and lower extremities and on the
face17. The clinical presentation of our patient, with miliary, mulaire and
nodule subdermal lesions, distributed in a disseminated form is unusual.
The observation of mucosal lesions is also infrequent. MAGUIÑA, in a
prospective series of 145 cases of Carrion’s disease, showed mucosal
compromise in 4 (3%) patients17. The lesions were found on oral and
nasal mucosa and on the ocular conjunctiva13,16,21,22.
The diagnosis of Carrion’s disease requires clinical, epidemiological
and laboratory information. The laboratory methods used frequently are
peripheral blood smears and histopathologic studies. The final diagnosis
in the acute phase uses the peripheral blood smears, which shows
parasitized red cells with the bacillary forms of B. baciliformis seen in
late phases some coccidial forms. The Romanovski, Giemsa and Wright
stains facilitate the identification of the microorganisms2,12,13,20. The final
diagnosis of the eruptive phase requires the demonstration of charac-
teristic histopathological changes such as proliferation of endothelial
cells, monocytes and macrophages, capillary proliferation, and in some
cases, cellular atypia3,4,13. The Warthin-Starry stain confirms the diagnosis,
allowing visualization of the bacteria. Other techniques include electron
microscopy and immunohistochemistry5.
The differential diagnosis of the eruptive phase of Carrion’s disease,
depending on the type of lesion, includes bacillary angiomatosis, Kaposi’s
sarcoma, pyogenic granuloma, hemangioma, fibrosarcoma, epithelial
sarcoma, cutaneous lymphoma, histioid phase of Hansen’s disease and
juvenile melanoma (Spitz tumor)2,13,20,22.
The treatment of Carrion’s disease depends on the stage. In the acute
phase, the treatment of choice is chloramphenicol for 10 to 14 days.
Quinolones, especially ciprofloxacin are alternative drugs12.
Chloramphenicol and ciprofloxacin have intracellular activity and
antibacterial effect against Gram-negative germs like Salmonella typhi
and non-typhoid species that usually complicate the course of the illness13.
In the eruptive phase, the treatment of choice is rifampin for 14-21 days.
Erythromycin, azithromycin, ciprofloxacin, and streptomycin have also
been used (C. Maguiña, personal communication). As seen in our patient,
ciprofloxacin represents a good alternative, for a period of 7-10 days13,16,17.
Treatment during this phase produces a decrease in size of the lesions in
7 days (range: 4 -14 days) and complete disappearance in 27 days (range:
14-70 days)16. In spite of good therapeutic results, larger clinical trials
are still necessary, which is often limited by the availability of patients
in the eruptive phase. The lesions are benign and spontaneously remit
without leaving a scar within 2-6 months.
Our report shows extension of Carrion’s disease and its presence in
the Peruvian forest, probably due to the continuous commerce carried
out among that region with settlers from in adjacent endemic zones. On
the other hand, it is also possible that the sandfly vector Lutzomyia
verrucarum and other species of Lutzomyia, potential transmitters of
the illness, have evolved. For these reasons, implementation of control
measures for this disease are necessary in Peru, including strategies of
entomological control, seroepidemiologic studies, and training of the
technical personnel and health workers in these areas.
RESUMO
Doença de Carrión (Bartonelose baciliforme) confirmada por
histopatologia na Selva Alta do Peru
A bartonelose ou doença de Carrión é endêmica em algumas regiões
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do Peru, descrevendo-se classicamente nos vales inter-andinos, entre
500 e 3.200 metros acima do nível do mar. Os autores relatam o caso de
um paciente de 43 anos de idade, fazendeiro, natural do distrito de
Pichanaki (Chanchamayo, Junín), localizado na Selva Alta do Peru. O
paciente apresentou-se com lesões disseminadas, elevadas e eritematosas,
algumas delas com sinais de sangramento. Distribuiam-se também na
mucosa nasal e no penis. Foram também observados nódulos subcutâneos
no tronco e nas extremidades. Os exames laboratorais evidenciaram
anemia moderada. Os testes sorológicos para detectar anticorpos contra
o HIV e Treponema pallidum foram negativos. Os resultados dos estudos
histopatológicos de duas biópsias de pele foram compatíveis com verruga
peruana. Iniciou-se antibioticoterapia com ciprofloxacina (500 mg duas
vezes ao dia). Após dez dias de tratamento, o paciente apresentou melhora
clínica importante. Este relato representa o primeiro caso autóctone
confirmado da fase eruptiva da bartonelose em um paciente da Selva
Alta do Peru, sugestiva da expansão geográfica da doença.
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